RAPP
Rapport TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-24
Current thesis
RAP-219 has already produced statistically significant Phase 2a proof-of-concept efficacy and tolerability data, management says FDA feedback supported advancement into two parallel Phase 3 trials, and the balance sheet plus Tenacia partnership provide time and some non-dilutive validation to pursue the program [#10-K-2026-03-10].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +15.9.
What can break
Cash burn accelerates as late-stage studies ramp, reviving dilution risk despite stated runway into 2H29.
Momentum
66
Value
41
Sentiment
36
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $38.00 · Bull $52.00 · Bear $24.00
Data freshness
Prices
As of 2026-07-24
Fundamentals
As of 2026-07-23 • Vendor: Data Vendor v1
Scores
As of 2026-07-24 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-24
Investment thesis
As of 2026-07-24
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $58.40
Why
Momentum66 · Δ7d +15.9
Value41 · Δ7d -0.0
Sentiment36 · Δ7d -2.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
66
26% active weight
Current posture
7d trendImproving
Δ7d
+15.9
Δ21d
+3.5
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.2
Sentiment
36
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.6
Δ21d
-10.4
Why this grade
Composite grade D. Momentum 65.9 / Value 41.1 / Sentiment 35.9
Fundamentals (TTM)As of 2026-07-23
Fundamentals (TTM)
As of 2026-07-23
Market Cap
$1.98B
Beta
-
Shares Out
47.83M
P/E (TTM) · Derived
-14.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-20.90
Rev YoY
-
EPS YoY
-38.4%
Gross Margin
+95.0%
Op Margin
-
Net Debt
-$479.16M
Current Ratio
27.08
As of 2026-07-24 • Updated nightlySource: Internal modelMethodology